Filters








1 Hit in 0.036 sec

Acromegaly Due to McCune–Albright Syndrome

Martin J Rutkowski, Derek G Southwell, Tyler M Cardinal, Lewis S Blevins, California Center for Pituitary Disorders, Department of Neurological Surgery, University of California, San Francisco, CA, USA, California Center for Pituitary Disorders, Department of Neurological Surgery, University of California, San Francisco, CA, USA, Department of Neurosurgery, Keck School of Medicine of University of Southern California, Los Angeles, CA, USA, California Center for Pituitary Disorders, Department of Neurological Surgery, University of California, San Francisco, CA, USA
2020 US Endocrinology  
M cCune-Albright syndrome (MAS) is characterized by polyostotic fibrous dysplasia, café-au-lait hyperpigmentation of the skin, and acromegaly. Ablative therapy in affected patients must target the entire pituitary gland, making medical management the preferred therapy. Targeted medical therapies, including somatostatin and growth hormone (GH) receptor blockade, have shown promise in achievement of biochemical remission. We present the case of a 15-year-old girl with MAS who was discovered to
more » ... as discovered to have pituitary enlargement on computed tomography scan. She presented with café-au-lait spots, fibrous dysplasia of the sphenoid bone, and elevated insulin-like growth factor 1 and GH levels that failed to suppress on oral glucose tolerance testing. Treatment with a somatostatin analog was shown to be a safe and effective long-term management strategy of acromegaly that provides advantages over surgical resection.
doi:10.17925/use.2020.16.1.47 fatcat:rd27fkdtyjg4fdhpp577r73diu